{
 "context": "The following article called 'Novartis Can Sell Copycat of Amgen's Neupogen in September' was published on 2015-07-21. The body of the article is as follows:\n    \nNovartis Can Sell Copycat of Amgen\u2019s Neupogen in September, Court Rules Zarxio would be first knockoff of a biotech drug By Jonathan.Rockoff@wsj.com July 21, 2015 2:25 p.m. ET \nA U.S. appeals court ruled Tuesday that Novartis AG could begin selling the first knockoff of a biotech drug on Sept. 2, a key step in efforts to contain spending on high-cost therapies through lower-priced competition. \nThe ruling by the U.S. Court of Appeals for the Federal Circuit in Washington clears a way for Novartis to begin sales of Zarxio, a knockoff of cancer supportive-care drug Neupogen, which is sold by Amgen Inc. Yet... To Read the Full Story, Subscribe or Sign In Popular on WSJ\n\n    The day before the article was published, the stock price of Amgen Inc. was 137.27207946777344 and the day after the article was published, the stock price of Amgen Inc. was ",
 "expected": "137.19691467285156",
 "date": "2015-07-21",
 "ticker": "AMGN",
 "company": "Amgen Inc."
}